Using nucleosome interacting protein domains to enhance targeted genome modification

Patent metadata

Field	Value
Publication number	US-12221606-B2
Application number	US-202016793253-A
Country	US
Kind code	B2
Filing date	Feb 18, 2020
Priority date	Jul 11, 2017
Publication date	Feb 11, 2025
Grant date	Feb 11, 2025

Abstract

Compositions and methods for using nucleosome interacting protein domains to increase accessibility of programmable DNA modification proteins to target chromosomal sequences, thereby increasing efficiency of targeted genome/epigenetic modification in eukaryotic cells.

First claim

What is claimed is:

1. A method for increasing cleavage efficiency of targeted genome modification or increasing epigenetic modification in a eukaryotic cell, the method comprising introducing into the eukaryotic cell:
(a) at least one fusion protein or nucleic acid encoding at least one fusion protein, each fusion protein comprising a Clustered Regularly Interspersed Short Palindromic Repeat (CRISPR) protein linked to at least one nucleosome interacting protein domain, wherein the CRISPR protein (i) has nuclease or nickase activity or (ii) is modified to lack all nuclease activity and is linked to a non-nuclease domain; and
(b) at least one guide RNA or nucleic acid encoding at least one guide RNA; wherein the CRISPR protein of the at least one fusion protein is targeted to a target chromosomal sequence and the at least one nucleosome interacting protein domain of the at least one fusion protein alters nucleosomal or chromatin structure such that the at least one fusion protein has increased access to the target chromosomal sequence, thereby increasing cleavage efficiency of targeted genome modification or increasing epigenetic modification, wherein the at least one nucleosome interacting protein domain is a high mobility group (HMG) box (HMGB) DNA binding domain, a HMG nucleosome-binding (HMGN) protein, a central globular domain from a histone H1 variant comprising SEQ ID NO: 45, or a combination thereof, wherein the CRISPR protein is a type II CRISPR/Cas9 protein or a type V-A CRISPR/Cpf1 protein.

2. The method of claim 1 , wherein the non-nuclease domain has cytosine deaminase activity, histone acetyltransferase activity, transcriptional activation activity, or transcriptional repressor activity.

3. The method of claim 1 , wherein the at least one nucleosome interacting protein domain is linked to the CRISPR protein directly via a chemical bond, indirectly via a linker, or a combination thereof.

4. The method of claim 1 , wherein the at least one nucleosome interacting protein domain is linked to the CRISPR protein at its N-terminus, C-terminus, or a combination thereof.

5. The method of claim 1 , wherein the at least one fusion protein further comprises at least one nuclear localization signal, at least one cell-penetrating domain, at least one marker domain, or a combination thereof.

6. The method of claim 1 , wherein nucleic acid encoding the at least one fusion protein is codon optimized for translation in the eukaryotic cell.

7. The method of claim 1 , wherein nucleic acid encoding the at least one fusion protein is part of a viral vector, a plasmid vector, or a self-replicating RNA.

8. The method of claim 1 , wherein the method further comprises introducing into the eukaryotic cell at least one donor polynucleotide, the donor polynucleotide comprising at least one donor sequence.

9. The method of claim 1 , wherein the eukaryotic cell is in vitro.

10. The method of claim 1 , wherein the eukaryotic cell is in vivo.

11. The method of claim 1 , wherein the eukaryotic cell is a mammalian cell.

12. The method of claim 1 , wherein the eukaryotic cell is a human cell.

13. The method of claim 1 , wherein said increased cleavage efficiency is measured by increased indel formation in said targeted genome in comparison to indel formation of said target genome when using essentially identical methods and employing a CRISPR protein not linked to at least one nucleosome interacting protein domain or wherein said increased epigenetic modification is measured by increased epigenetic modification or transcriptional regulation in comparison to epigenetic modification or transcriptional regulation of said target when using essentially identical methods and employing a CRISPR protein that is not linked to at least one nucleosome interacting protein domain.

Assignees

• Sigma Aldrich Co Llc

Inventors

• Chen Fuqiang
• Ding Xiao
• Feng Yongmei
• Davis Gregory

Classifications

• C12Q1/6897

  involving reporter genes operably linked to promoters · CPC title

• C12N2800/80

  Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites · CPC title

• C12N15/907

  in mammalian cells · CPC title

• C12N15/85

  for animal cells · CPC title

• C12N15/113

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title